We are live on ! Find out more
MRKR icon

Marker Therapeutics

5 hedge funds and large institutions have $119K invested in Marker Therapeutics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 0%0.04% (+0.04%)

Holders
5
Holders Change
+5
Holders Change %
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
1
Millennium Management
New York
$95K +$115K +2,461 New
PAM
2
Panagora Asset Management
Massachusetts
$23K +$31.6K +678 New
AG
3
Advisor Group
Arizona
$1K +$1.3K +28 New
Morgan Stanley
4
Morgan Stanley
New York
+$47 +1 New
IA
5
IFP Advisors
Florida
+$372 +8 New

MRKR Hedge Fund Activity: Q4 2016 in Review

5 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2016, worth a combined $119K.

Buyers outnumbered sellers: 5 funds opened new MRKR positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $115K.

  • 5 institutional investors held Marker Therapeutics (MRKR) as of Q4 2016, up from 0 in Q3 2016.
  • Funds reported $119K of Marker Therapeutics stock for Q4 2016.
  • 5 funds opened new Marker Therapeutics positions in Q4 2016 and 0 closed out, a net change of +5 holders.
  • The largest Marker Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $115K added.

Based on aggregated 13F filings for Q4 2016.